The effect of ertugliflozin in patients with nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus.

Phase 3

• Conditions: Fatty liver diseases; Obesity; Elevated liver enzymes; Insulin resistance; Non alcoholic acute Steatohepatitis (NASH); Metabolic and Endocrine - Metabolic disorders; Metabolic and Endocrine - Diabetes; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

• Registration Number: ACTRN12624000032550
• Lead Sponsor: Abdul Wali Khan University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2024-01-15
• Last Update Posted: 29 January 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

Participants for this RCT must be Adult patients (above age of 20 years), diagnosed with non alcoholic fatty liver diseases along with type 2 diabetes mellitus.

Exclusion Criteria

Participants not having non alcoholic fatty liver diseases along with type 2 diabetes mellitus., not willing to participate and the patient having elevated liver enzyme with any other risk factor such as hepatitis.

Study & Design

• Study Type: Interventional
• Study Design: Not specified